5"Cr-release assays, EIAV-specific cytotoxic activity was detected in unstimulated PBMC from three infected horses. The EIAV-specific cytotoxic activity was major histocompatibility complex (MHC) restricted, as determined by assaying EIAV-infected heterologous EK targets, and was mediated by CD8+ T lymphocytes, as determined by depleting these cells by a panning procedure with an anti-CD8 monoclonal antibody. MHC-restricted CD8+ CTL in unstimulated PBMC from infected horses caused significant specific lysis of autologous EK cells infected with recombinant vaccinia viruses expressing EIAV genes, either env or gag plus 5' pol. The EIAV-specific MHC-restricted CD8+ CTL were detected in two EIAV-infected horses within a few days after plasma viremia occurred and were present after viremia was terminated. The detection of these immune effector cells in EIAV-infected horses permits further studies to determine their in vivo role.
Among lentivirus infections, the disease caused by equine infectious anemia virus (EIAV) has distinctive features during both the acute clinical and the subsequent asymptomatic carrier stages. Horses with EIAV have an initial plasma viremia and associated fever, anemia, and thrombocytopenia occurring as early as I to 2 weeks after infection (4, 19, 38, 42) . The initial viremia is usually terminated (19, 42) , and viremic episodes and clinical disease of a duration of several days may recur. Occurrence of viremic episodes correlates with the appearance of viral antigenic variants which are resistant to existing neutralizing antibody (21, 35, 40) . Despite antigenic variation of epitopes recognized by neutralizing antibody (21, 35) and other possible mechanisms of viral escape from immune responses, most horses control EIAV and become clinically quiescent virus carriers (5) . These carriers have extremely small amounts of virus in their blood (6) , indicating that the virus is effectively controlled.
The mechanisms by which horses eventually control EIAV are unknown, although evidence indicates that immune responses are involved. Foals with genetically transmitted severe combined immunodeficiency disorder and lacking only B-and T-lymphocyte function are unable to clear the initial viremia associated with EIAV infection (42) . That (509) 335-8529. control by immune responses (20) . Several immune mechanisms directed against viral proteins could be involved in control of EIAV. Antibodies to Env protein epitopes cause either viral neutralization (9, 15) or possible destruction of cells expressing Env or other proteins by antibody-dependent cellular cytotoxicity (22) or complement lysis (12) . In human immunodeficiency virus type 1 (HIV-1)-infected humans, cytotoxic T lymphocytes (CTL) recognize epitopes from several viral proteins, including Env, Gag, Pol, Nef, and Vif proteins (36, 39, 44, 50) , and CTL recognizing epitopes on similar simian immunodeficiency virus (SIV) proteins are present in infected rhesus monkeys (2, 31, 52, 53) .
Knowledge of the relative roles of the various immune responses in preventing lentivirus infections and in controlling infections once they occur is needed to design effective vaccines and immunologic interventions (13) . Thus, CTL were investigated to begin dissecting immune responses involved in the termination of plasma viremia in acute EIAV infection and in EIAV control in asymptomatic carriers. Since major histocompatibility complex (MHC)-restricted CTL to EIAV-infected cells had not been clearly described, cell targets for demonstrating cytotoxicity were identified, and an assay was developed to detect CTL in unstimulated peripheral blood mononuclear cells (PBMC) from infected horses. MHC-restricted cytotoxic activity was found in unstimulated PBMC that caused significant specific lysis of EIAV-infected equine kidney (EK) cell cultures. Depletion of CD8+ T lymphocytes removed the EIAV-specific MHC-restricted CTL activity. Vi (34, 37) . A percutaneous renal biopsy was taken from a 10-month-old female (H521), and 1 month later, the horse was infected with 108 TCID50 of EIAVWsU5. Similarly, a renal biopsy was taken from a 6-year-old male (H525), and 2 weeks later, the horse was infected with 108 TCID5( of EIAVwsu5.
Rectal temperature was taken daily (three times per week), the blood packed-cell volume was measured, and plasma virus titer was determined by using EK cell cultures (37, 42 (49) was used to make a singlebase mutation in pEIASE to remove an early vaccinia virus transcription terminator signal, TTTTTNT (8) . Sequencing confirmed that a synonymous C was substituted for T at position 2080 and that no other changes were introduced. VSC1 I was a control recombinant made with pSC1 1. After recombination with WR strain vaccinia virus (26) , recombinants were identified by ,B-galactosidase expression (3), and Env protein expression was verified by immunoblotting. Selected recombinants were plaque purified three times on BSC-1 cells.
Immunoblots to detect Env proteins. EK cell cultures in 15(-cm2 flasks with Dulbecco modified Eagle medium and 5% bovine serum were infected with 10 PFU of VEnvl, VEnv2, or VSC1 1 per cell. Ten minutes before infection, medium from one group of flasks was removed, and medium with 40 p.g of cytosine arabinoside per ml was added (8) . Cells were removed after incubation for 2, 4, or 24 h at 37°C; washed three times with phosphate-buffered saline (PBS); and lysed on ice for 30 min in 50 mM Tris hydrochloride (pH 8.0) with 5 mM EDTA, 5 mM iodoacetamide, 1 mM phenylmethylsulfonyl fluoride, 0.1 mM N-tosyl-L-lysine chloromethyl ketone, and 0.5% Nonidet P-40. Lysates were cleared by centrifugation (9,000 x g for 5 min), separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to nitrocellulose, and immunoblotted with equine monoclonal antibodies (MAbs) from equine-murine xenohybridomas (41) . Equine MAb 30/8.12 recognizes EIAV SU (gp9O), and MAb 30/249.2 recognizes TM (gp45) (41) . Bound MAb was detected with antibodies to equine immunoglobulin conjugated to horseradish peroxidase and visualized by chemiluminescence (28) .
Northern (RNA) blots of RNA from recombinant vaccinia virus-infected cells. After infection of EK cells with VEnvl or VEnv2, 100 p.g of cycloheximide per ml was added (8) . Cultures were incubated at 37°C for 2 h and then rinsed, and cells were removed by scraping. Total RNA was extracted with guanidine thiocyanate and homogenization and then centrifuged through cesium chloride (47) . Ten micrograms of RNA per lane was separated in a 1.2% formaldehyde gel, transferred to GeneScreen Plus nitrocellulose, baked at 80°C for 2 h, and hybridized with a 329P-labeled BamHI-Xbal env fragment (1).
Depletion of CD8+ T lymphocytes from PBMC. Isolated PBMC were depleted of CD8+ T lymphocytes by using an anti-equine CD8 MAb covalently bound to a surface-activated flask. Briefly, 250 p.g of anti-CD8 MAb HT14A (23) in 5 ml of 0.01 M sodium phosphate-0.15 M NaCl (pH 7.4) (PBS) was added to MicroCELLector surface-activated cell culture flasks (Applied Immune Sciences, Santa Clara, Calif.) and incubated for I h at room temperature. After washing and blocking flasks with 0.2% bovine serum albumin (BSA) in PBS, 3 x 107 PBMC which had been blocked with 10% autologous serum in PBS were added to each flask and incubated at room temperature for 1 h. Nonadherent cells were collected for evaluation and use in CTL assays.
Immunofluorescence flow cytometry. PBMC (107/ml) were suspended in PBS with 0.5% BSA and 0.02% sodium azide, both before and after depletion of CD8+ T lymphocytes. Next During this period, the horse had antibodies to p26 but was afebrile (<39°C), and no plasma viremia or anemia was detected. However, PBMC taken 7 weeks after infection caused low-level, but significant, specific lysis of EIAV-infected cells. The percent specific lysis of EIAV-infected EK cells was defined as significant when it exceeded the percent specific lysis of noninfected EK cells by 2.5 SE. The maximum specific lysis (13.5%) occurred with PBMC taken at 27 weeks and used at an E:T cell ratio of 50:1 for 17 h (Fig. 1) . Both 6-and 17-h assay times resulted in significant specific lysis of EIAVinfected cells by PBMC (Fig. 1) . Since percent specific lysis was higher with 17-h assays, this time was used in subsequent assays. The range of 5'Cr spontaneous release in most 17-h assays was 15 to 31%. On the basis of this and a similar range in a CTL study using 18-h assays (14) , assays with a spontaneous release exceeding 32% were not used. Mixtures with E:T cell ratios of 10:1 and 50:1 were assayed, and EIAV-specific lysis was always greater with a 50:1 ratio.
Unstimulated PBMC from H521 infected with 108 TCID5, of EIAVWSU5 caused remarkable specific lysis of EIAVwsU5-infected autologous EK cells (Fig. 2) . By using an E:T cell ratio of 50:1, the maximum percent specific lysis of noninfected EK target cells by PBMC was 5.4% over 100 days (Fig. 2) . No cytotoxic activity was detected in PBMC taken before and 1 week after infection; however, PBMC taken 2 weeks after infection caused 29.2% specific lysis (Fig. 2) . The maximum specific lysis (55.3%) of EIAVwsU5-infected autologous EK cells occurred with PBMC taken 7 weeks after infection. The amount of specific lysis of infected EK cells by PBMC decreased to 13% at 9 weeks and increased again to 27% at 14 weeks after infection (Fig. 2) . Plasma viremia was detected in H521 at 7 to 26 days after infection, with a peak virus titer of 103 8 TCID5(/ml detected on day 9 (Fig. 2) . Plasma viremia was terminated by day 28, and no viremia was detected between days 28 and 100; day 100 was the last day evaluated. No fever or anemia were detected in the 100-day observation period.
PBMC from H525 infected with 108 TCID,() of EIAVwSLJ5, the same dose as for H521, were examined for cytotoxic activity against EIAVWS55-infected autologous EK cells (Fig. 3) .
Unstimulated PBMC from H525, 21 days after infection and at an E:T cell ratio of 50:1, caused 48.5% specific lysis of EIAV-infected EK target cells and 2.4% specific lysis of uninfected EK target cells. Plasma viremia was detected at day 8, peaked on day 20 at 102-'TCID5(/ml, and was terminated by day 39 (Fig. 3) . Thrombocytopenia occurred at day 18 and reached a minimum of 45,000 platelets per pLI on day 22 (data not shown). PBMC collected at 42 and 56 days after infection, times when viremia was terminated and thrombocyte counts had returned to normal, also caused significant specific lysis of EIAV-infected EK cells. The cause of relatively high percent specific lysis of uninfected autologous EK cells on days 28 and 42 (17 and 13%, respectively) is unknown, as lysis of heterologous EK cells did not occur.
MHC restriction of EIAV-specific, PBMC-mediated cytotoxicity. PBMC from H525 at 6 weeks after infection, which caused 24% specific lysis of autologous EK cells infected with EIAVWSU5, caused only 2.2% specific lysis of EIAVwsU5-infected EK cells from an unrelated horse, H521 (Fig. 4) . Similarly, PBMC from H521 at 4 weeks after infection, which caused 49.4% specific lysis of EIAVwsU5-infected autologous EK cells, caused only 5.3% specific lysis of non-MHC-matched EIAVwsU5 -infected EK cells from an unrelated horse, H507 (Fig. 5) . These data indicated that over 90% of the EIAVspecific cytotoxicity was MHC restricted and not attributable to antibody-dependent cellular cytotoxicity mechanisms including CD16+ lymphocytes armed with EIAV-specific antibody (44, 52) .
Effect of depletion of CD8+ T lymphocytes on EIAV-specific, MHC-restricted, PBMC-mediated cytotoxicity. CD8+ T lymphocytes were removed from unstimulated PBMC of H525 and H521 at 10 and 20 weeks after infection, respectively, by a panning procedure with MAb HT14A to equine CD8. Specific (Fig. 6) . PBMC from H521 containing 11% CD8+ T lymphocytes caused 23.8% specific lysis of EIAV-infected EK cells, while those PBMC depleted of CD8+ T lymphocytes (<0.6% CD8+ remaining) caused 6.6% specific lysis of the same target cells (Fig. 6 ). This demonstrated that 72 to 76% of the EIAVspecific, MHC-restricted CTL activity in these PBMC was mediated by CD8+ T lymphocytes.
Characterization read-through occurred, was also made. In contrast, EK cells infected with VEnv2 made only the complete 2.5-kb env transcript (Fig. 7) , confirming alteration of the termination signal.
The Env proteins made by EK cells infected with VEnvl and VEnv2 (mutated) were compared by immunoblotting with defined MAb to EIAV SU and TM (41) . The amounts of Env proteins made at 2 and 4 h after infection were less in VEnvlthan in VEnv2-infected cells (Fig. 8) ; however, similar amounts of these proteins were present at 24 h. Four hours after infection, both lysates had proteins reactive with anti-SU MAb at 125 and 105 kDa (Fig. 8A) , interpreted as Env precursor and SU (43, 46) . At (Fig. 8B ). These were interpreted, respectively, as Env precursor, TM, and a proteolytic product of TM identified as gp35 in other studies (43) . The minor bands reacting with anti-TM MAb in 24-h lysates and the 55-kDa protein in 4-h VEnv2-infected lysates were probably Env protein intermediates of proteolytic processing. Cytosine arabinoside was added to VEnvl-and VEnv2-infected EK cells to inhibit DNA synthesis and, thereby, late protein synthesis by the vaccinia virus P7.5 promoter that was used to express EIAV env (P7.5 has both early and late promoter activities [8] ). This treatment decreased production of all Env proteins, but the decrease was more marked in cells infected with VEnvl. This demonstrated that mutation of the transcription termination signal enhanced P7.5-promoted early protein synthesis but had little effect on J. VIROL. late protein synthesis. VEnv2 was used to infect EK target cells because of these data and because (i) transcription termination signal removal from HIV-1 env enhanced antibody in mice immunized with vaccinia virus expressing this gene (8) and (ii) levels of endogenously processed antigen may determine whether an epitope and class I MHC complex is efficiently presented to and recognized by class I-restricted CTL (33) .
EIAV-SPECIFIC, MHC-RESTRICTED CD8+ CTL
MHC-restricted CD8+ CTL of vaccinia virus-infected target cells expressing Env or Gag/PR proteins. PBMC containing MHC-restricted CD8+ CTL to EIAVwsu5-infected EK cells were tested for CTL activity on EK cell targets infected with VEnv2-expressing EIAV env, VGag/PR-expressing gag and 5' pol genes, or VSC1 1 control recombinant vaccinia virus. PBMC from H521 at 8 weeks after infection and used at an E:T cell ratio of 50:1 caused 18.2% specific lysis of VEnv2-infected autologous EK cells compared with 9.8% for VSC1 1-infected cells (Fig. 9) . When the VSC1 1-and VEnv2-infected cells were treated with UV light for 2 min 17 h after infection to inhibit vaccinia virus replication during the CTL assay, there was 1.2 and 10.3Cc specific lysis, respectively (Fig. 9) . Studies with PBMC from H525 taken 6 weeks after infection and used at an E:T cell ratio of 50:1 caused 32.0 and 13.3% specific lysis of EIAVwsU5-infected and noninfected autologous EK cells, respectively (Fig. 10) . These PBMC also caused 29.6, 22.6, and 15.7% specific lysis of VEnv2-, VGag/PR-, and VSCI 1-infected autologous EK cells, respcctively (Fig. 10) fibroblasts (10) . The mechanism of the previously reported EIAV-specific, non-MHC-restricted equine PBMC cytotoxic activity is unknown. However, similar observations with PBMC from human patients seropositive to HIV-1 (27, 44) and SIV-infected rhesus monkeys (52) have been reported and attributed to CD16+ MHC class I-unrestricted cells. There is another report of MHC-restricted specific lysis (6.5 and 8.4%) of EIAV-infected cells by PBMC from 2 of 11 horses with acute EIAV infection (11) . The target cells used in this report were autologous PBMC from the EIAV-infected horses stimulated with phytohemagglutinin for 72 h (11) . Since EIAV is not known to replicate in lymphocytes and the number of infected monocytes was not determined, it is difficult to interpret these findings. No other reports of PBMC-mediated cytotoxicity of EIAV-infected cells are known.
That the EIAV-specific, MHC-restricted CTL in PBMC from infected horses were mediated by CD8+ T lymphocytes was determined by depletion studies. The CD8+ T lymphocytes were removed from freshly isolated PBMC by a panning procedure with an anti-CD8 MAb, HT14A (23) (24, 25) . However, most MHCrestricted CTL from HIV-seropositive humans and SIV-infected rhesus monkeys are CD8+ (14, 32, 52) . To determine whether EIAV env or gag-5' pol-encoded proteins were recognized by EIAV-specific, MHC-restricted CD8+ CTL from PBMC, recombinant vaccinia viruses expressing either EIAVWSUS env or gag plus 5'pol genes were used to infect autologous EK cell targets. CTL from one horse caused significant percent specific lysis of target cells expressing Env, while CTL from a second horse caused significant percent specific lysis of cells expressing either Env or Gag/PR proteins. Since EK cell targets infected with recombinant vaccinia viruses were not evaluated for every assay in which EIAVspecific MHC-restricted CTL were demonstrated, it is not known whether both horses would have recognized Gag proteins. Furthermore, it is not known whether CTL detected by reactivity to EIAV-infected cells also recognize epitopes encoded by pol and other genes which encode regulatory proteins described for CTL from HIV-1-seropositive humans (36, 44) and SIV-infected rhesus monkeys (2, 36) . In many HIV-1 and SIV studies, CTL have not been detected by using lentivirusinfected target cells, but the studies have used either recombinant vaccinia viruses expressing lentiviral genes or synthetic peptide-charged target cells. Therefore, it is possible that further identification of the epitopes recognized on EIAVinfected cells by primary CTL from infected horses that are successfully controlling EIAV will yield new information. TARGET CELLS FIG. 10. MHC-specific CD8+ CTL in unstimulated PBMC from H525 at 6 weeks after infection were assayed for cytotoxicity of autologous EK cells (columns 1 to 5) or heterologous EK cells (columns 6 to 10) infected with EIAV or recombinant vaccinia viruses. Target cells in columns 1 and 6 were noninfected, those in 2 and 7 were EIAVwsu5 infected, those in 3 and 8 were VSC1 1 infected, those 4 and 9 were VEnv2 infected, and those in 5 and 10 were VGag/PR infected. The E:T ratio was 50:1, assay time was 17 h, and spontaneous release did not exceed 32%. Vertical lines on columns are SEs (48).
In conclusion, the demonstration of EIAV-specific, MHCrestricted CD8+ CTL in unstimulated PBMC of EIAV-infected horses as early as 2 weeks after infection and persisting for several months provides an important system to dissect unstimulated CTL responses to lentivirus-infected target cells. The CTL assay, particularly the use of EIAV-infected autologous EK cells, should also be useful in dissecting the mechanism of protective immunity induced by experimental vaccines to EIAV (16) . In fact, the protective immunity induced by immunization with inactivated EIAV was correlated with activated T lymphocytes and thought to be mediated in some horses by CTL (16 
